Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation.
about
Cardiac cachexia: hic et nuncPharmacology of manipulating lean body massThyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?Ventricular assist devices: pharmacological aspects of a mechanical therapyMechanisms of metabolic dysfunction in cancer-associated cachexiaThe role of metabolic syndrome in heart failureTreatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animalsNutritional deficiency in Dutch primary care: data from general practice research and registration networks.Nutritional and anti-inflammatory interventions in chronic heart failure.The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia.Defects in insulin action in chronic heart failure.Malnutrition in patients suffering from chronic heart failure; the nurse's care.Clinical nutrition: 1. Protein-energy malnutrition in the inpatient.Protein intake and bone growth.Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease.Effects of ghrelin treatment on exercise capacity in underweight COPD patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatmentReduced handgrip strength as a marker of frailty predicts clinical outcomes in patients with heart failure undergoing ventricular assist device placementCardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD).Ghrelin: integrative neuroendocrine peptide in health and disease.Cardiac cachexia.Future prospects of anticytokine therapy in chronic heart failure.Exploring metabolic dysfunction in chronic kidney disease.Circulating Omega-6, But Not Omega-3 Polyunsaturated Fatty Acids, Are Associated with Clinical Outcomes in Patients with Acute Decompensated Heart Failure.Body mass index, change in body mass index, and survival in old and very old persons.Prognostic value of nutritional screening tools for patients scheduled for cardiac surgeryLong-term effects of ghrelin and ghrelin receptor agonists on energy balance in ratsCardiac cachexia at a glance.Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS).The prognostic value of anemia in patients with diastolic heart failure.Influence of etiology of heart failure on the obesity paradox.Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks.Age-associated remodeling of neural and nonneural thymic catecholaminergic network affects thymopoietic productivity.Nutrition intervention in the critically ill cardiothoracic patient.The older patient with heart failure: high risk for frailty and cognitive impairment.Determinants of survival following hospitalization for acute heart failure.Upregulation of cardiac ghrelin mRNA in leptin-deficient and leptin receptor-deficient mice with viral myocarditis.Electrocardiographic abnormalities in treatment-naïve HIV subjects in south-east Nigeria.Muscle wasting in heart failure : The role of nutrition.Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.
P2860
Q26744140-CA910C9B-AA55-4A22-A1F5-A3C62B7D8EFBQ26824503-2FB6F596-D7A2-4686-9A06-A324D129A441Q26995671-E009897B-71C1-4AC4-AF42-E5A37B3A4778Q27002612-B1C2F62D-DBBE-487C-B726-37A7588FDF35Q28079213-CC706EA8-FA4A-4F4A-BA63-674B2D403751Q28085668-7F2A11E8-D461-4200-9C2D-CF3A418DBE7EQ28570699-1B141B6F-2B8C-4D9A-AD04-0D1678D50EC3Q30997165-49CF2821-7AD9-439A-8BD2-84E650466993Q33880185-9BED866F-4A04-4672-8971-ED2E2300EDE2Q33948639-4A69920B-AA34-4182-A676-3BBE3D1DFF73Q34166305-D8DB0FE0-D2BE-4654-A05F-D14E14B7F2FDQ34340600-DB483248-4E84-4247-9B5E-C2332B5E427EQ34473337-5B1F7930-9A5F-4A35-901B-7DFAD5675913Q34565780-228E30E4-B4EC-4CD5-8899-CB473B5355F0Q34625439-8CF4F718-B8F8-4732-BB1F-0A30F529220FQ34768351-5B0BC447-52AE-46D8-8155-50080A176AEEQ34824162-7185030B-817C-4ACE-B21E-C296729424D8Q35545370-96382154-C3A2-4138-AE0D-84654535BACFQ35667712-EFBEB1C4-93E0-4263-B47C-0BC6DF161C47Q35692577-FD761DF3-81B8-4690-9FA9-2C1D82CE0AD4Q35932382-62BD7B8D-19E5-4329-908A-1655F5351866Q36087238-1FC27A49-5942-4DA6-9408-C3A7B281C1C4Q36123347-4F3412A4-5C93-473B-A070-03BCFBF78228Q36185678-130FC67F-CBFA-4476-8841-9D46EB09E698Q36771236-001090D9-DB64-4CDD-8229-464376CC7C4AQ36778596-BA95E553-0D39-42F7-B0AD-EDBF80120E48Q36805444-F35E9C42-1FAB-4C51-9121-ABA1A05620B9Q36836579-146704F6-8F66-4C34-B70C-C5FC09DDB5D2Q37176492-1174BDF4-02B7-4773-8119-DD90A99FB7A5Q37227861-1A0C6D6C-5A3E-4FF6-8BFF-C9ECAA6C78B7Q37394595-459897C0-EECD-480A-9B3D-B332F2DEFD1AQ37893657-1A289D7C-ACBA-4F0C-863B-A55F6012A118Q37939602-5A90FCC2-9C0D-4F93-BDFB-8AF91115C8ADQ38003838-3FE8B9ED-62F4-4D1F-B3AC-831A2126CD9FQ38034810-01BBAE33-947A-4C25-A234-1162AF5E9CE6Q38183318-15DA22E0-C98E-4488-B691-461A29C6ACB3Q38346230-53897D3C-DD64-4489-87E4-8E19C46E8583Q38874462-1C494682-FDEC-4129-A6C1-3F7ABF0B66E4Q38985792-3ACA4ECC-353A-4F5E-B079-CEB0C17AD370Q39052397-A11403D2-BD6B-44F6-9EC0-FB49F0871040
P2860
Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cardiac cachexia: a syndrome w ...... and neuroendocrine activation.
@ast
Cardiac cachexia: a syndrome w ...... and neuroendocrine activation.
@en
Cardiac cachexia: a syndrome w ...... and neuroendocrine activation.
@nl
type
label
Cardiac cachexia: a syndrome w ...... and neuroendocrine activation.
@ast
Cardiac cachexia: a syndrome w ...... and neuroendocrine activation.
@en
Cardiac cachexia: a syndrome w ...... and neuroendocrine activation.
@nl
prefLabel
Cardiac cachexia: a syndrome w ...... and neuroendocrine activation.
@ast
Cardiac cachexia: a syndrome w ...... and neuroendocrine activation.
@en
Cardiac cachexia: a syndrome w ...... and neuroendocrine activation.
@nl
P356
P1433
P1476
Cardiac cachexia: a syndrome w ...... and neuroendocrine activation.
@en
P2093
P304
P356
10.1378/CHEST.115.3.836
P407
P577
1999-03-01T00:00:00Z